Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Duchenne Muscular Dystrophy

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Nephrology

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

PTSD

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Skin Cancer

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

Emerging Leaders

Interactive Tools

PBM Leaders

PBMI Innovators

Subscribe

Videos

Joe DePinto from McKesson discussed the challenges facing cell and gene therapies, particularly around reimbursement, and highlighted successful strategies to speed up access. He also shared optimism for the future, with many products already achieving blockbuster status and more expected by 2030.

Overcoming Barriers to Access in Cell and Gene Therapy | Asembia’s AXS25 Summit

Joe DePinto, MBA, head of cell, gene and advanced therapies at McKesson , met with MHE at the annual Asembia Specialty Pharmacy Summit in Las Vegas this week to give some insight on where we are with cell and gene therapies, as well as looking at Pfizer's discontinued hemophilia B gene therapy, Beqvez (fidanacogene elaparvovec-dzkt).

Screenshot 2025-04-29 at 5.04.42 PM.png

Are Cell and Gene Therapies Overpromised or Facing Growing Pains | Asembia's AXS25 Summit

A future where healthcare may include augmented reality, robots and drones may be more fact than fiction, says George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.

Do Robots Have a Place in Healthcare? | Asembia's AXS25 Summit

As healthcare AI evolves, there will be a greater emphasis on streamlining administrative tasks, drug production and service delivery, according to George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics. 

AI is a Physician Complement, Not Replacement, Expert Says | Asembia's AXS25 Summit

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

Dermatology Conference Coverage

AMCP Annual

K-Cast: Optimizing Narcolepsy Care

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

In this month’s episode, Briana Contreras, an editor of 

 Editorial Advisory Board Member, Ateev Mehrotra, MD, MPH, who is a professor of healthcare policy at Harvard Medical School and an Associate Professor of Medicine and Hospitalist at Beth Israel Deaconess Medical Center. 

What’s been on Ateev’s mind or has been a focus, lately, are most things in the digital health and telehealth space, as well as practice licensure in the U.S. Among many topics discussed in the conversation, Ateev shared his thoughts on the push for better virtual visit opportunities and the fact that insurers are now offering virtual first health plans with lower premiums. 


Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of catching up with MHE Editorial Advisory Board Member, Ateev Mehrotra, MD, MPH, who is a professor of healthcare policy at Harvard Medical School and an Associate Professor of Medicine and Hospitalist at Beth Israel Deaconess Medical Center. 

In the Scope of Virtual Health and the Future of “Website” Manner, Per Ateev Mehrotra

In this week’s episode of "Tuning In to the C-Suite," Briana Contreras, editor of Managed Healthcare Executive, spoke with Ramin Bastani, CEO of Healthvana. Ramin addressed the ongoing issue of underserved communities lacking access to care and shared the efforts made specifically through digital health to help. He also discussed the steps that remain to be taken to improve access to care.

In this week’s episode of "Tuning In to the C-Suite," Briana Contreras, editor of Managed Healthcare Executive, spoke with Ramin Bastani, CEO of Healthvana. 

The Ongoing Battle to Improve Access to Care Through Digital Health, per Ramin Bastani of Healthvana

In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.

Meet the Board: Ateev Mehrotra of Harvard Medical School Talks About Telehealth Issues, Price Transparency, His Latest Hobby and More

In this week's episode, Briana Contreras, editor of Managed Healthcare Executive, spoke with Peter Durlach, chief strategy officer of Nuance. The two discussed how artificial intelligence drives value for patients and providers and how AI tools and solutions are helping health systems reach the quadruple aim of care.


Peter Durlach of Nuance Talks on How Artificial Intelligence Drives Value for Patients and Providers

Briana Contreras, editor of Managed healthcare Executive, spoke with Dr. Ian Tong, chief medical officer of Included Health in today’s episode. The two discussed telehealth use vs. in person care, and more specifically, the racial and ethnic differences in this use of care. They concluded the conversation with how telehealth use has continued to expose more benefits for all patients and for the industry through examples like improvements in reimbursement policies and in addressing health equity issues.


Dr. Ian Tong of Included Health Addresses Racial Differences in Telehealth Use

In this week’s episode Briana Contreras, associate editor of Managed Healthcare Executive, met with Greg Miller, vice president of Industry Strategy, Healthcare and Life Sciences at Talkdesk. The two discussed that while virtual care has become a convenient tool in healthcare during the pandemic and has helped treat more patients, this form of care isn’t completely solving patient’s underlying issues. However, Miller shared how AI is helping ease the patient experience and improving care in this conversation.

Greg Miller of Talkdesk Discusses How AI is Easing the Patient Experience in Care

In this week’s episode, Managed Healthcare Executive Associate Editor Briana Contreras had the pleasure of meeting CEO of Quanterix and founder of Powering Precision Health, Kevin Hrusovsky. Quanterix is a blood-based biomarker analysis company. In this discussion, the two discussed Powering Precision Health and some tools like the Disruptive Innovation 5-step model that brings his vision closer of detecting and improving the health of patients sooner. 


Kevin Hrusovsky of Quanterix Shares Successful Tools Toward Improving Precision Health and More

Managed Healthcare Executive had a conversation with Kelly Chillingworth, RPh, director of business development at RxBenefits this week about the unique connection between pharmacy and telemedicine, what impact telemedicine & its pharmacy costs have on self-funded employers and how the right virtual care services a health provider offers to their members can be essential to building a competitive benefit. 

The Connection Between Telehealth, Pharmacy and How it Affects Self-Funded Employers

Briana Contreras, associate editor of MHE, spoke with Edmundo Gonzalez, CEO of Marpai Health, for this week's episode of Tuning In to the C-Suite podcast. The two talked about the significance of AI and deep learning in healthcare and how they will benefit the self-insurance market. 


The Significance of AI, Deep Learning in the Self-Insurance Market

Briana Contreras of MHE spoke with Josh Claman, CEO of Rimidi about the strong need for a permanent remote patient monitoring, or RPM, reimbursement reform, and how our health industry can come together to influence this change. The two also discussed the benefits of RPM technology for underserved, uninsured or Medicaid populations, and the benefits of RPM during and beyond the COVID-19 pandemic. 


The Need for Permanent RPM Reimbursement, Benefits of RPM Beyond COVID-19

Few question the benefits of adopting a universal healthcare data exchange standard but achieving that goal will prove to be difficult.

FHIR Idea Burns Bright.  Implementation Flickers

The technology to leverage healthcare data exists. The problem, according to Highlander Health, is outdated structures and silos.

Want to Improve Patient Care? Waste Not the Data

Artificial intelligence is quickly becoming a valuable tool in the U.S. healthcare industry. Experts say a thoughtful approach can head off ethical problems and optimize efficiency.

How AI is Changing Healthcare

Telehealth has become a permanent part of U.S. healthcare delivery, 
and states are taking steps to regulate it

Telehealth is a Go, and States Are Having Their Say So

Artificial intelligence gains foothold in the emergency room as a note-taking aid.

The Doctor Will See You Now, But AI May Be Listening In

Bronwyn Spira of Force Therapeutics talked to Managed Healthcare Executive about CMS' new CPT codes that were introduced in 2022. These codes help more patients in underserved populations receive better access to care as barriers like cost and transportation are removed through remote care. 

"In releasing these codes, CMS was very thoughtful about creating boundaries or minimal requirements," Spira said. "Because we want to make sure that these patients are receiving care that has parity to in-person care." 

She added that it's crucial the outcome of care is delivered as expected by the patient when it comes to reimbursed care.

How CMS CPT Codes Are Assisting Underserved Musculoskeletal Patients

"It's really important, as we think about virtual care being reimbursed, that the care delivers the outcomes that patients expect and that those outcomes are being measured and delivered back to the care team," Spira said. "It really has to be a true ecosystem of care. All care should be predicated on delivering an outcome to the patients."

In this second part of a two-part video series, Bronwyn Spira of Force Therapeutics talked to Managed Healthcare Executive about CMS' new CPT codes that were introduced in 2022. These codes help more patients in underserved populations receive better access to care as barriers like cost and transportation are removed through remote care.

Reimbursable Remote Care For Patients in Need, The Future of Remote Care

Founder and managing partner of Third Culture Capital (3CC), Julien Pham, chatted with 

about alternative routes to care outside of telehealth. Pham expressed that funding for telehealth is on the decline and will only continue on this path. He explained why this is happening and shared those alternative routes of care organizations can take to address disparities and improve access to care.

Founder and managing partner of Third Culture Capital (3CC), Julien Pham, expressed that funding for telehealth is on the decline and will only continue on this path. Pham explained why this is happening and shared alternative routes of care organizations can take to address disparities and improve access to care.

Alternative Ways to Address Disparities Outside of Telehealth

In this final video of a two-part video series, Jason Warrelmann, global director of Healthcare and Life Sciences at UiPath, addressed why automation is necessary for patients and providers and how other healthcare organizations can better overcome the challenges of adopting automation within their health system.


Jason Warrelmann of UiPath Shares Patient Benefits of Automation, Tips for Orgs Adopting Automation

In this first of a two-part video series, Jason Warrelmann, global director of Healthcare and Life Sciences at UiPath, addressed the incline of automation in healthcare, why it's necessary for patients and providers and how other healthcare organizations can better overcome the challenges of adopting automation within their health system.

Jason Warrelmann of UiPath Addresses the Incline of Automation and its Importance in Healthcare

Below is a brief Q&A of the interview with Reynolds. It has been edited for clarity.

Q: Do you see any potential for overuse of telehealth and remote care?

 It's is interesting because, personally, I love the telehealth. I love the fact that I don't have to drive to a doctor's office and sit in there and kill two hours of my time for a five-minute assessment. That said, I think there's probably some care that can only be done for the patient at the doctor's office. There's some tests that you need to go in person for - the the lot of the the assessments that a clinician might want to make, whether that's body weight, visibly looking at a patient's body, collecting blood pressures, things like that need to be in person. I do think that telehealth is likely here to stay, especially for some therapeutic areas versus others. I think that we've seen a huge rise in the mental health usage of telehealth. Definitely others as well. 

It's interesting because when we wrote this paper, one of the critical issues was the switch from typical medical assessments to telehealth. I took it upon myself to take a look at the literature and see that is it effective, where's it effective, who's effective, and the literature is still fairly mixed. I found a systematic review of reviews and of those about a quarter found that the telehealth was effective, a quarter found that there was some suggestive evidence, but it was unclear. The other half of it really had incomplete or non positive findings. That said, I still can't take much away because when I started digging through those studies, the types of clinicians using it, the type of therapies being used, what they call telemedicine, there are all of the different diseases being incorporated here. There was such heterogeneity. I don't know that there's an easy takeaway.  

I do think that over the next year or so we're going to be seeing more and more studies come out to say, "does it work here?", "Does this type of teletherapy work?", "Does this teletherapy work better than this one?" You know, really understanding the factors associated with effective telehealth. I don't think we're there yet. I think it's starting to come out. Those insights I think will help to drive whether we're going to overuse it or potentially that we're not even using it enough.

Q: Has the pandemic-associated decline in utilization perhaps winnowed out some low-value care? If so, any particular tests or services? If not, why?

 I have seen some papers here that have talked about low-value care really more tied to the overuse of services and procedures and such that maybe don't have a lot of benefit or cause results in patient dissatisfaction when compared to their utility in their benefit. It seems like things such as, potentially, some screenings or diagnostic tests, laboratory test, use of antibiotics, overuse of antibiotics; there are a list of things that I think are being evaluated now that I've seen in 

, a number of these others where we have thought leaders talking about assessing this, but I have not seen results come through yet. 

Given that I'm an epidemiologist and not someone who specializes in say managed care or even health economics per se, it's tough for me to answer that question, but I do expect that will be one benefit of this pandemic we likely will find out some of the services we really didn't need and or provided very low utility or marginal benefit. Don't know what those answers are yet. I gave a couple of examples, but those are those are all secondhand from what I've read from the experts in this field.

Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses his appreciation for telehealth and remote care, but feels over the next year or so we're going to be seeing more studies come out questioning if some telehealth is needed in certain areas. The discussion came from findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research.

ISPOR: Matthew Reynolds of IQVIA Addresses Potential Overuse of Telehealth

 Associate Editor, Briana Contreras, speaks with CEO of Virtual Health, Adam Sabloff, who discusses the transformation of value-based care in healthcare and what he thinks the future may look like for value-based care after COVID and the presidential election.

In this part two of three video series, CEO of VirtualHealth, Adam Sabloff, discusses the role technology plays in providing a whole-person view as a component in value-based care and how the election will impact the future of this specific type of care.

How Tech, Upcoming Election Influence Future of Value-Based Care

speaks with CEO of Virtual Health, Adam Sabloff, who discusses the transformation of value-based care in healthcare and what he thinks the future may look like for value-based care after COVID and the presidential election.

In this part one of three video series, CEO of VirtualHealth, Adam Sabloff, discusses the birth of the healthcare services institution, what it's offering to the industry and how value-based care, in particular, is transforming especially because of COVID-19.

How COVID-19 Impacts the Move Toward Value-Based Care

Jim Beiermann, CFO, and Danny Irland, senior vice president of network operations and chief network officer of Southwestern Health Resources discuss their focus of value-based care through ACO and Next Generation Programs within the company with Managed Healthcare Executive Senior Editor, Peter Wehrwein.

Jim Beiermann, Danny Irland of Southwestern Health Resources Talk ACO, Next Gen. Programs (Pt. 2)

Jim Beiermann and Danny Irland, both of Southwestern Health Resources, discuss their focus of value-based care through ACO and Next Generation Programs.

Jim Beiermann, Danny Irland of Southwestern Health Resources Talk ACO, Next Generation Programs (Pt. 1)

Here are some excerpts shown and not shown in our interview with Lisa Griffin, vice president of front-end operations Jefferson Health. They have been edited for length and clarity.

I am finished my dissertation around that subject in a healthcare environment, so it is close to my heart to make sure that we're dealing with those things.

Peter Wehrwein, senior editor at Managed Healthcare Executive, spoke with Lisa Griffin, senior vice president of front-end operations at Jefferson Health in Philadelphia, about the pivot to telehealth, "seamless access" and racism.


Technology

Latest News